| Valbenazine Tosylate | Neurocrine Bioscience | ||
| 40, 60, and 80 mg ; Capsules |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| None | None | ||
| INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: Tardive dyskinesia. Chorea associated with Huntington’s disease. | |||
|
Yes
| |||
| Ingrezza Sprinkle | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** ****** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** |
| *********** ***** *** ********** ******* | *********** ***** *** ********** ******* | *********** ***** *** ********** ******* | *********** ***** *** ********** ******* | ******* *** *** ************** ** ******* ***** ********** | ******* *** *** ************** ** ******* ***** ********** | ******* *** *** ************** ** ******* ***** ********** | ********* ******* *** *********** ** (*)-(**,**,****)-*-********-*,**-*********-*,*,*,*,*,***-*********-**-******[*,*,-*]***********-*-*-*****-*-*************** **(*-**********************) | ********* ******* *** *********** ** (*)-(**,**,****)-*-********-*,**-*********-*,*,*,*,*,***-*********-**-******[*,*,-*]***********-*-** *-*****-*-*************** **(*-**********************) | ******* *** *** ************** ** ******* ***** ********** | ********* ******* *** *********** ** (*)-(**,**,****)-*-********-*,**-*********-*,*,*,*,*,***-*********-**-******[*,*-*]***********-*-** *-*****-*-*************** **(*-**********************) | ******* *** *** ************** ** ******* ***** ********** | ******* *** *** ************** ** ******* ***** ********** | ******* *** *** ************** ** ******* ***** ********** | ******* *** *** ************** ** ******* ***** ********** | **** ****** *********** *********** *** ************, *******, *** **** ******* ******* | ******* *** *** ************** ** ******* ***** ********** | **** ****** *********** *********** *** ************, *******, *** **** ******* ******* | *********** *-********-*,**-*********-*,*,*,*,*,***-*********-**-******[*,*-*]***********-*-** ********* *** ******* ******** ******* | *********** *-********-*,**-*********-*,*,*,*,*,***-*********-**-******[*,*-*]***********-*-** ********* *** ******* ******** ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** ****** | *** \ *** | **** **, **** | ******* | **** | *** ****** **** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|